

Anton Hagenbeek
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.

LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071209_anton_hagenbeek.mp3]